Compare STRIDES PHARMA SCIENCE with Wockhardt - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

STRIDES PHARMA SCIENCE vs WOCKHARDT - Comparison Results

STRIDES PHARMA SCIENCE     Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

WOCKHARDT 
   Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    STRIDES PHARMA SCIENCE WOCKHARDT STRIDES PHARMA SCIENCE/
WOCKHARDT
 
P/E (TTM) x 15.6 -23.9 - View Chart
P/BV x 0.9 1.3 73.3% View Chart
Dividend Yield % 0.5 0.0 17,192.8%  

Financials

 STRIDES PHARMA SCIENCE   WOCKHARDT
EQUITY SHARE DATA
    STRIDES PHARMA SCIENCE
Mar-18
WOCKHARDT
Mar-18
STRIDES PHARMA SCIENCE/
WOCKHARDT
5-Yr Chart
Click to enlarge
High Rs1,1471,012 113.3%   
Low Rs642532 120.8%   
Sales per share (Unadj.) Rs317.2355.9 89.1%  
Earnings per share (Unadj.) Rs7.8-60.3 -13.0%  
Cash flow per share (Unadj.) Rs25.1-46.8 -53.6%  
Dividends per share (Unadj.) Rs2.000.01 20,000.0%  
Dividend yield (eoy) %0.20 17,255.4%  
Book value per share (Unadj.) Rs274.3257.8 106.4%  
Shares outstanding (eoy) m89.50110.63 80.9%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.82.2 130.0%   
Avg P/E ratio x114.0-12.8 -890.6%  
P/CF ratio (eoy) x35.7-16.5 -216.3%  
Price / Book Value ratio x3.33.0 109.0%  
Dividend payout %25.50 -153,677.2%   
Avg Mkt Cap Rs m80,05885,379 93.8%   
No. of employees `0002.56.3 40.1%   
Total wages/salary Rs m4,3419,371 46.3%   
Avg. sales/employee Rs Th11,325.86,295.0 179.9%   
Avg. wages/employee Rs Th1,731.41,498.3 115.6%   
Avg. net profit/employee Rs Th280.1-1,066.3 -26.3%   
INCOME DATA
Net Sales Rs m28,39439,369 72.1%  
Other income Rs m9411,202 78.2%   
Total revenues Rs m29,33440,571 72.3%   
Gross profit Rs m3,96518 21,668.9%  
Depreciation Rs m1,5401,495 103.0%   
Interest Rs m1,9622,555 76.8%   
Profit before tax Rs m1,403-2,830 -49.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m-1680-   
Extraordinary Inc (Exp) Rs m-436-3,582 12.2%   
Tax Rs m97257 37.9%   
Profit after tax Rs m702-6,669 -10.5%  
Gross profit margin %14.00 30,044.6%  
Effective tax rate %6.9-9.1 -76.3%   
Net profit margin %2.5-16.9 -14.6%  
BALANCE SHEET DATA
Current assets Rs m24,83633,796 73.5%   
Current liabilities Rs m18,99326,917 70.6%   
Net working cap to sales %20.617.5 117.8%  
Current ratio x1.31.3 104.1%  
Inventory Days Days7179 89.4%  
Debtors Days Days11389 127.1%  
Net fixed assets Rs m34,28939,664 86.4%   
Share capital Rs m895553 161.8%   
"Free" reserves Rs m23,65127,968 84.6%   
Net worth Rs m24,54628,522 86.1%   
Long term debt Rs m15,51321,731 71.4%   
Total assets Rs m65,43781,620 80.2%  
Interest coverage x1.7-0.1 -1,595.1%   
Debt to equity ratio x0.60.8 83.0%  
Sales to assets ratio x0.40.5 90.0%   
Return on assets %4.1-5.0 -80.8%  
Return on equity %2.9-23.4 -12.2%  
Return on capital %6.9-7.7 -89.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m15,6979,807 160.1%   
Fx outflow Rs m7351,789 41.1%   
Net fx Rs m14,9628,019 186.6%   
CASH FLOW
From Operations Rs m1,871684 273.3%  
From Investments Rs m5,8266,302 92.4%  
From Financial Activity Rs m-10,157-7,695 132.0%  
Net Cashflow Rs m-2,615-664 393.8%  

Share Holding

Indian Promoters % 27.7 74.5 37.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 37.8 2.3 1,643.5%  
FIIs % 8.6 7.7 111.7%  
ADR/GDR % 0.0 0.1 -  
Free float % 25.9 15.4 168.2%  
Shareholders   56,241 67,757 83.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare STRIDES PHARMA SCIENCE With:   CADILA HEALTHCARE  J.B.CHEMICALS  ORCHID PHARMA LTD  BIOCON   FULFORD INDIA  

Compare STRIDES PHARMA SCIENCE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

WPI Inflation Data, Global Stock Market Drivers, and Top Cues in Focus Today(Pre-Open)

On Monday, Indian share markets witnessed negative trading activity throughout the day and ended lower.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (1QFY20); Net Profit Up 1048.1% (Quarterly Result Update)

Jul 31, 2019 | Updated on Jul 31, 2019

For the quarter ended June 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 432 m (up 1048.1% YoY). Sales on the other hand came in at Rs 7 bn (up 3.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (4QFY19); Net Profit Up 7919.8% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, STRIDES PHARMA SCIENCE has posted a net profit of Rs 650 m (up 7919.8% YoY). Sales on the other hand came in at Rs 8 bn (up 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

STRIDES PHARMA SCIENCE SHARE PRICE


Sep 16, 2019 (Close)

TRACK STRIDES PHARMA SCIENCE

  • Track your investment in STRIDES PHARMA SCIENCE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON STRIDES PHARMA SCIENCE

STRIDES PHARMA SCIENCE 8-QTR ANALYSIS

COMPARE STRIDES PHARMA SCIENCE WITH

MARKET STATS